The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

about

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

Item

http://www.wikidata.org/entity/Q47820469

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

@en

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

@nl

type

Item

label

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

@en

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

@nl

prefLabel

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

@en

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.

@nl

P1476

The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia

@en

P2093

Colleen E Annesley

http://www.w3.org/2001/XMLSchema#string

Corinne Summers

http://www.w3.org/2001/XMLSchema#string

Rebecca A Gardner

http://www.w3.org/2001/XMLSchema#string

P2860

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

Designing chimeric antigen receptors to effectively and safely target tumors

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Current concepts in the diagnosis and management of cytokine release syndrome.

P304

591-598

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.950

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Ceppi

P577

2017-12-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29171004

http://www.w3.org/2001/XMLSchema#string